Bacopa Monnieri (Brahmi)
Updated October 11, 2026 · By Sophie Callahan
The Short Answer
Bacopa monnieri (Brahmi) is an Ayurvedic herb with a growing body of clinical evidence supporting its role in memory formation, learning, and cognitive processing speed. Standardized extracts containing 20–55% bacosides are used in clinical trials at doses of 300–600 mg/day, with benefits typically emerging after 4–12 weeks of consistent use. It is one of the most studied botanical nootropics, with multiple randomized controlled trials in both healthy adults and elderly populations.
What is Bacopa Monnieri (Brahmi)?
Bacopa monnieri, also known as Brahmi or water hyssop, is a perennial creeping herb native to the wetlands of South Asia, Australia, and parts of Africa. It has been used in Ayurvedic medicine for centuries as a memory-enhancing herb (medhya rasayana). The active compounds — triterpenoid saponins called bacosides (particularly bacosides A and B) — are responsible for its cognitive effects. Modern supplements standardize their extracts to a specific bacoside content, typically 20–55%, to ensure consistency across batches.
How it works
Bacopa monnieri's cognitive effects operate through multiple pathways. Bacosides enhance synaptic communication by modulating the activity of acetylcholine, serotonin, and dopamine — three neurotransmitters central to memory, mood, and attention. Bacopa also promotes dendritic branching and synaptogenesis in the hippocampus, the brain region most directly involved in forming new memories. Additionally, bacosides exhibit antioxidant activity, reducing oxidative stress in neural tissue and supporting long-term neuronal health. The herb's effects are cumulative rather than acute: most clinical trials require 4–12 weeks of daily supplementation before measurable cognitive improvements emerge.
What the evidence says
Bacopa monnieri is one of the most clinically studied botanical nootropics. The evidence base includes multiple randomized controlled trials in healthy adults, elderly populations, and children, with most trials using standardized extracts at 300–600 mg/day.
- Bacopa monnieri (CDRI-08) improved sustained cognitive performance in a dose-dependent manner at 320 mg and 640 mg. — A double-blind, placebo-controlled crossover study in healthy adults testing acute effects of 320 mg and 640 mg CDRI-08 Bacopa extract on sustained cognitive performance tasks. (Downey et al., 2013 (Crossover RCT))
- Standardized Bacopa extract improved cognitive function, anxiety, and depression scores in healthy elderly subjects. — A randomized, double-blind, placebo-controlled trial of a standardized whole-plant Bacopa extract in healthy elderly participants, measuring cognitive performance, anxiety, and depression. (Calabrese et al., 2008 (RCT))
Effective dosage
Clinical trials have used 300–600 mg/day of standardized Bacopa extract. A 2013 crossover RCT by Downey et al. tested acute doses of 320 mg and 640 mg of CDRI-08 extract and found dose-dependent improvements in cognitive performance. Earlier trials by Stough et al. (2001) and Roodenrys et al. (2002) used 300 mg/day for 12 weeks. The extract should be standardized to at least 20% bacosides. Bacopa is fat-soluble and is better absorbed when taken with a meal containing dietary fat. Effects are cumulative — most subjects in clinical trials required 4–12 weeks before measurable improvements in memory or learning emerged.
Safety and interactions
Bacopa monnieri is generally well tolerated at doses up to 600 mg/day in clinical trials lasting up to 12 weeks. The most commonly reported side effects are mild gastrointestinal symptoms: nausea, stomach cramps, and increased bowel frequency, which typically resolve within the first week of use. Bacopa may interact with thyroid medications and anticholinergic drugs. It has mild sedative properties at higher doses, which can be beneficial for stress-related cognitive support but may cause drowsiness in sensitive individuals. No serious adverse events have been reported in published clinical trials.